Trial details
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: EMPOWHER 303
Official title: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Principal Investigator: Dr. Rossanna Pezo
Cancer type: Breast
Cancer location: Breast
Disease stage: Advanced Cancer
Trial phase: Phase 3
Intervention:
Registration #:
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Trial description:
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
